| “We Must Deliver On Our Promise To Lower The Amount Of Money Our Constituents Pay For Prescription Drugs” |
| WASHINGTON, D.C. — As congressional Democrats work to add drug pricing provisions, including Medicare negotiation, into the Build Back Better Act, 15 frontline House Democrats sent a letter yesterday to Speaker Pelosi and Majority Leader Hoyer urging immediate action to address the high price of prescription drugs. Led by Rep. Angie Craig (MN-02), the letter is signed by Reps. Colin Allred (TX-32), Cindy Axne (IA-03), Sharice Davids (KS-03), Josh Harder (CA-10), Steven Horsford (NV-04), Andy Kim (NJ-03), Susie Lee (NV-03), Lucy McBath (GA-06), Tom Malinowski (NJ-07), Chris Pappas (NH-01), Elissa Slotkin (MI-08), Abigail Spanberger (VA-07), Lauren Underwood (IL-14), and Susan Wild (PA-07). “On behalf of patients all across this country, we want to thank Congresswoman Craig and these members of Congress who are going to the mat fighting to add Medicare negotiation to lower drug prices back into the Build Back Better plan,” David Mitchell, a cancer patient and founder of Patients For Affordable Drugs Now, said in Rep. Craig’s press release. “Medicare negotiation is supported by 90 percent of voters who are depending on Congress to deliver years of promises to provide relief to patients struggling to afford their prescription medications. These members know that the moment for action is now to enact meaningful reforms that will fix a rigged system and restore balance to ensure we get the innovation we need at prices we can afford. The fight is not over, and we are proud to stand with these members.” Momentum has been building over the weekend to ensure that the most popular provision — allowing Medicare to negotiate lower drug prices — is included in the Build Back Better Act. Congressional leaders have been working to agree on meaningful provisions for the package that would lower prices for patients. Democratic members on both sides of the Capitol have been clear that Medicare negotiation must be included in the final package. Last week, Patients For Affordable Drugs Now and AARP demanded Congress add drug pricing reform into the Build Back Better Act. Patients For Affordable Drugs Now called the lack of its inclusion in the president’s framework “a huge failure” and AARP said it is “outraged” by the exclusion. Read the full letter here and below. |
| October 31, 2021 The Honorable Nancy Pelosi Speaker U.S. House of Representatives Washington, D.C., 20515 The Honorable Steny Hoyer Majority Leader U.S. House of Representatives Washington, D.C., 20515 Dear Speaker Pelosi and Majority Leader Hoyer: Thank you for your leadership and continued efforts to lower the cost of prescription drugs. As majority-makers in competitive districts, we promised our constituents that we would come to Washington to fight on their behalf for lower drug prices. We cannot turn back now on our promise to the American people. We urge you in the strongest terms possible to include legislative language in the Build Back Better Act that will be voted on by the full House to accomplish this. The pharmaceutical industry has gouged the American public for decades. As a country, we spend hundreds of billions of dollars a year on prescription drugs, and yet our constituents must often choose between purchasing prescribed medications or putting food on the table. It is unacceptable that anyone in the wealthiest country in the world cannot access the medications they need to stay alive. With two lobbyists per Member of Congress, we know that Big Pharma is deeply invested in the status quo. Our current system forbids Medicare from negotiating the prices it pays for prescription drugs. As a result, millions of Americans are forced to spend thousands of dollars a year on their medications – or go without. In many cases, as with insulin, these medications have been on the market for decades. In 1991, a bottle of Humalog insulin cost $21. Today the average list price is over $300. That is inexcusable. In these instances, we are not paying for research and development. By allowing the cost of drugs like insulin to rise year after year, we are financing soaring executive salaries, stock buybacks and outrageous profit margins on the backs of our seniors. With the Build Back Better agenda, we have a perhaps once in a generation opportunity to change the status quo and make good on our promise that no one should have to choose between affording their prescription drugs or food or housing. The public is on our side. Big Pharma is not. Soon, we must go back to our districts and explain what we’ve done in Washington to make our constituents’ lives better. We ran on upsetting the status quo and lowering out-of-pocket costs for healthcare and prescription drugs. If we fail, we’ll need to explain to them why we let Big Pharma win, why we let entrenched special interests take precedence over the American people. You have dedicated your careers to lowering the cost of healthcare. We stand with you in your continued efforts. The moment is now. We must deliver on our promise to lower the amount of money our constituents pay for prescription drugs. We must demonstrate that we work for the American people and not the pharmaceutical industry. Our constituents are counting on us. |
| ### |
WASHINGTON, D.C. — As Congress works to finalize the framework for the president’s Build Back Better plan, AARP and Patients For Affordable Drugs Now sent a letter to Speaker Pelosi and Leader Schumer today urging them to include the most popular provision — allowing Medicare to negotiate lower drug prices. The letter identifies key elements that the legislation must include to fulfill promises to meaningfully lower prices for patients: negotiation on the highest-priced drugs, drugs covered under both Medicare Parts D and B, and drugs without meaningful competition; penalties for annual price increases that exceed the rate of inflation; and a hard cap on annual out-of-pocket costs for Medicare patients.
“This is the moment to enact legislation that will help millions of Americans who are forgoing drugs they have been prescribed but cannot afford, rationing, and choosing between paying rent or paying for prescriptions they need,” Nancy A. LeaMond, Executive Vice President and Chief Advocacy and Engagement Officer at AARP, and David Mitchell, cancer patient and founder of Patients For Affordable Drugs Now, say in the letter.
Right now, Americans are forced to pay three times what other wealthy nations pay for the same medicine. Even after hearing the industry’s false claims that negotiation will bring harm to patients and consumers, more than 8 out of 10Americans support allowing Medicare to negotiate.
Read the full letter here and below.
| ### |
| WASHINGTON, D.C. — 160 patient advocates from over 40 states who are leading the drug pricing reform fight with Patients For Affordable Drugs Now sent a letter to Speaker Pelosi today expressing strong support for the inclusion of comprehensive Medicare negotiation in the Build Back Better Act. “Momentum is building in Congress to pass drug pricing legislation that will bring real relief to patients who are struggling to afford prices that are almost four times what patients in other wealthy nations pay for the exact same brand-name drugs,” said Lauren Stanford, a diabetes patient and P4ADNow’s Community Organizing Director who leads work mobilizing a community of more than 360,000 patients and allies. “Patients have waited too long. It’s time for Congress to deliver its promise to lower drug prices and let Medicare negotiate.” The letter was sent following the inclusion of comprehensive legislation that allows Medicare to negotiate lower prices out of the House Ways And Means and Budget Committees, and before it heads to the Rules Committee, where it may be amended prior to a floor vote as part of the reconciliation package. The Senate Finance Committee is also currently drafting legislation that will allow Medicare to negotiate, which would deliver on the president’s Build Back Better plan under rules of reconciliation. Read the full letter below. Patient activist leaders are available to speak to media upon request. |
 September 27, 2021 The Honorable Nancy Pelosi Speaker of the House H-232, The Capitol Washington, D.C. 20515 Dear Speaker Pelosi, As a national community of patients whose lives are directly affected by the high prices of prescription drugs in this country, we write to express our strong support for inclusion of strong and effective drug pricing measures in the Build Back Better Act — most importantly, direct Medicare negotiation. This historic moment and these comprehensive reforms offer a once-in-a-generation opportunity to deliver urgently needed relief to patients like us. Too many of us struggle to afford prices that are almost four times what patients in other wealthy nations pay for the exact same brand-name drugs. Nearly 40 percent of Americans have trouble affording their prescription drugs, and more than 20 percent have had to take on debt or declare bankruptcy due to medication prices in the past year. We are grateful for innovative medicines that help manage our conditions and improve our health. But these statistics demonstrate our lived reality and compel us all to face a fundamental fact: Drugs don’t work if people can’t afford them. The pharmaceutical industry wants us to believe we must choose: Let drug corporations have unfettered pricing power or say farewell to innovative new medicines. But that’s a false choice. Countless analyses have demonstratedthat it is possible to restore balance and achieve affordable medications without sacrificing true innovation. Medicare negotiation that pays the best prices for the best drugs would reward clinically meaningful new drugs and actually stimulate investment in innovation. The Build Back Better Act is complemented by the president’s budget, which would invest more funds in the National Institutes of Health to further stimulate research. Moreover, it is critical to remember that many patients can’t afford existing drugs they require today. As many as 1.1 million Americans will die in the next decade because they can’t afford needed medication. We’re confident that inclusion of comprehensive drug pricing reforms in the reconciliation package will lower prices, save lives, and ensure continued development of innovative new drugs. The provisions under consideration will provide relief to Americans by allowing Medicare to negotiate directly with drug companies for lower prices, capping annual out-of-pocket costs in the Medicare prescription drug program, and stopping pharmaceutical price gouging by penalizing price increases that outpace inflation in both the private and public sectors. Patients have waited too long. It’s time for Congress to deliver its promise to lower drug prices and let Medicare negotiate. Signed: Adeline Toevs, allergies, Buena Vista, CO Allison Wheeler, type 1 diabetes and fibromyalgia, Gaithersburg, MD Amy Miller, systemic lupus erythematosus, Grants Pass, OR Andrea Nowakowski, Crohn’s disease, postural orthostatic tachycardia syndrome, depression, and traumatic brain injury, St. John, IN Ann Neilson, chronic dry eye, fibromyalgia, osteoarthritis, back injury resulting in a discectomy and subsequently a lumbar fusion, Madras, OR Anne Goddard, mother of a daughter with type 1 diabetes, Haverhill, MA Ashley Suder, systemic lupus erythematosus, Morgantown, WV Becky Hall, metastatic breast cancer, Capitola, CA Candice Brown, ulcerative colitis, Alexandria, VA Caroline Walsh, Turner syndrome, psoriatic arthritis, and celiac disease, Quincy, MA Catherine Benitz, Sjogren’s syndrome, Greeley, CO Cayley Winters, type 1 diabetes, Battle Creek, MI Chris Burgess, psoriatic arthritis, Chicago, IL Chuck Hurley, myasthenia gravis, Annapolis, MD Clayton McCook, father of a daughter with type 1 diabetes, Edmond, OK Connie Lindy, Xarelto patient, Middletown, DE Dan Kass, diabetes, Mission, KS David Mitchell, multiple myeloma, Bethesda, MD Deanna Robinson, chronic lymphocytic leukemia and type 2 diabetes, Mazeppa, MN Deb Withrow, interstitial cystitis, International Falls, MN Debra Armus, bipolar disorder, Delray Beach, FL Debra Ford, adrenocortical carcinoma, Nanuet, NY Dirk Last, type 1 diabetes, Minneapolis, MN Donald M. Kreis, parent of person with cystic fibrosis, Concord, NH Donna L. Pingrey, chronic pain and pacemaker, Colusa, CA Donna Renfroe, acid reflux and high cholesterol, Atlanta, GA Elaine Pierce, glaucoma, San Antonio, TX Elizabeth Kanfush, blood clotting disorder, Monaca, PA Ella Westerfield, asthma and chronic migraine, Denver, CO Emily Grant, cystic fibrosis, Dallas, TX Gail deVore, type 1 diabetes, Denver, CO Gary Gross, polycythemia vera, Montgomery, OH Genevieve Scott, ulcerative colitis, Charlotte, NC Ginny Boynton, Lambert-Eaton myasthenic syndrome, Mechanicsburg, PA Glenda Smith, chronic obstructive pulmonary disease, Kennebunk, ME Hailey Adkisson, mother of Juniper, who has a rare form of epilepsy, Salem, OR Hattie Saltzman, type 1 diabetes, Kansas City, MO Heidi Daniels, diabetes, Arlington, MA Heidi Kendall, chronic myeloid leukemia, Portola Valley, CA Helen Sgarlat, spondylolisthesis, spondylitis, and degenerative disc disease, Forty Fort, PA Iesha Meza, type 1 diabetes, Phoenix, AZ Jacqueline Garibay, ankylosing spondylitis, Austin, TX Jacqueline Gray, caregiver, Portland, OR Jacqueline Trapp, multiple myeloma, Muskego, WI Jacquie Persson, Crohn’s disease, Waterloo, IA Janet Kerrigan, RN, advocate, and ambassador for patients and families dealing with myeloma, Myrtle Beach, SC Janet Schwartz, multiple sclerosis and type 2 diabetes, Newark, DE Jay Gironimi, cystic fibrosis and diabetes, Groton, CT Jayme Thode, spina bifida, Quechee, VT Jesse Nagel, father of a person with type 1 diabetes, Belle Harbor, NY Joan Raider, chronic obstructive pulmonary disease, heart failure, atrial fibrillation, lung cancer, stage 4 kidney failure, diabetes, thyroid deficiency, and arthritis, Carrollton, GA Joan Tramontano, gastrointestinal stromal tumor, Venice, FL Joanna Olson, B-cell lymphoma, Beaverton, OR John Meaney, 5q minus syndrome, Bonita, CA Joyce Allex Schultz, multiple myeloma, Ceylon, MN Julia Bartow, Crohn’s disease and gastroparesis, Boston, MA Dr. Julia Blanchette, type 1 diabetes, Cleveland Heights, OH Julie F. Miller, multiple sclerosis and Crohn’s disease, Providence, RI Justine Miner, type 2 diabetes, Bristol, CT Karolina Chorvath, Crohn’s disease, Boston, MA Kat Schroeder, type 1 diabetes, Arlington, VA Katherine Pepper, asthma, diabetes, and gastroparesis, Bellingham, WA Keith Van Houten, father of a son with Duchenne muscular dystrophy, West Bloomfield Township, MI Kelly Shanahan, metastatic breast cancer, South Lake Tahoe, CA Ken Oleksa, multiple myeloma, atrial fibrillation, and glaucoma, Gibsonia, PA Kimberly Ishoy, type 1 diabetes, South Jordan, UT Kirk Tinsley, type 2 diabetes, Bowling Green, KY Kolton Chapman, ulcerative colitis, type 2 diabetes, Moyamoya disease, Pickerington, OH Kristen Smith, mother to children with autism spectrum disorder and type 1 diabetes, Plymouth, MA Kristina Caffrey, Gaucher disease, Albuquerque, NM Kristopher Fabian Garcia, asthma, Denver, CO L. Rose McMahan, asthma and type 2 diabetes, Fairfield, CA Lauren Stanford, type 1 diabetes, Washington, DC Laurie Rozgonyi, chronic diarrhea, Mill Creek, WV Leah Clark, Crohn’s disease, Ann Arbor, MI Lesley A. Nadeau, multiple sclerosis, Royal Oak, MI Lija Greenseid, parent of child with type 1 diabetes, Saint Paul, MN Lisa Trainor, post-traumatic stress disorder and attention-deficit/hyperactivity disorder, Princeton, NJ Lisette Pylant, nerve pain disorder and post-traumatic stress disorder, Andover, MA Liz Westerfield, asthma, Rockland, ME Loree Ulrich, multiple sclerosis, Saint Charles, MO Lori Dumont, sister of a person with type 1 diabetes, Brewer, ME Lori Lee Roden, mother of a person with type 1 diabetes, Madison, WI Lucy Gibson, type 1 diabetes, Washington, DC Lucy Westerfield, irritable bowel syndrome, Washington, DC Luz Lopez, chronic fibromyalgia and cervical and lumbar radiculopathy, Phoenix, AZ Lynn Scarfuto, chronic lymphocytic leukemia, Herkimer, NY Marcus LaCour, type 1 diabetes, Cincinnati, OH Margaret Wright-Mueller, fibromyalgia, pinched nerves, and lupus, Littleton, CO Maria Sanchez, diabetes, Atlanta, GA Mary Mack, heart transplant recipient, Nantucket, MA Matt Navey, Crohn’s disease, Durham, NC Maureen Iten, seizure disorder, non-Hodgkin’s lymphoma, and follicular thyroid cancer, Shoreview, MN Meg Jackson-Drage, fibromyalgia, Magna, UT Melissa Evans, asthma and kidney disease, Wilkes-Barre, PA Melissa Fleming, multiple myeloma, Morgantown, WV Michelle Rzeplinski, diabetes, Pottsville, PA Mike Nielsen, husband of wife with hepatitis C, Bend, OR Miriam Wolfe, Crohn’s disease and chronic pain, York, ME Moira McCarthy Stanford, mother of a person with type 1 diabetes, Plymouth, MA Nancy Cartwright, widow of multiple myeloma patient, Las Vegas, NV Natasha Yoder, several conditions, Lancaster, PA Nicole Smith-Holt, mother of son who died from rationing insulin, Richfield, MN Nilton Leon, type 2 diabetes, Santa Ana, CA Noelle Tuominen, mother of two children with type 1 diabetes, Livermore, CA Norma Alicea Berrios, type 2 diabetes, Copperas Cove, TX Pamela Holt, multiple myeloma, Granger, IN Patricia McKenzie, type 2 diabetes, Lithonia, GA Patricia Tenney, chronic allergies and sinusitis, Holyoke, MA Patrick Lewis, obsessive-compulsive disorder, Davenport, IA Paul Kleutghen, primary plasma cell leukemia, Southport, NC Pranav Pinapala, type 1 diabetes, Houston, TX Rachel Burnett, Crohn’s disease, Pittsburgh, PA Rachel Clark, type 1 diabetes, Arlington, VA Rachel Conner, obsessive-compulsive disorder, Nashville, TN Ramae Hamrin, multiple myeloma, Bemidji, MN Randall Barker, type 1 diabetes, Iowa Park, TX Rebecca Hovde, Lambert-Eaton myasthenic syndrome, Wellman, IA Robert Fowler, multiple myeloma, North Ridgeville, OH Robert Krawetzki, diabetes and spinal stenosis, Berlin Heights, OH Robert Porter, multiple myeloma, Mackinaw, IL Ronit Zemel, chronic dry eye, Falls Church, VA Rose Keller, cystic fibrosis, Norwich, VT Russell Saltzman, type 1 diabetes, Kansas City, MO Sa’Ra Skipper, type 1 diabetes, Indianapolis, IN Sabrina Burbeck, mother of son with type 1 diabetes, Old Town, ME Sam McLaren-Fahey, Lyme disease, celiac disease, chronic inflammatory response syndrome, and hypothyroidism, Washington Township, MI Samantha M. Sawyer, spondyloarthritis, Boston, MA Samantha Norris-Dubrul, B.A.A, J.D., Hodgkin’s lymphoma, Macomb Township, MI Samantha Rynearson, Crohn’s disease, North Platte, NE Sandra Killett, multiple myeloma, New York, NY Sanie Mikaelian, blood cancer, San Francisco, CA Sarah Duhart Clarke, type 1 diabetes, hypothyroidism, and attention-deficit/hyperactivity disorder, Vancouver, WA Sascha Martin, type 1 diabetes, Providence, RI Savanna Braun, severe allergic asthma and psoriatic arthritis with spondylitis and enthesitis, The Woodlands, TX Scarlett Woodard, multiple sclerosis, Albany, GA Scott Ensworth, cardiac amyloidosis, Beaver Falls, PA Sharon Brown, pulmonary hypertension, Kingsport, TN Sheila Porter, multiple myeloma, Mackinaw, IL Sheldon Armus, atrial fibrillation, Boynton Beach, FL Sneha Dave, ulcerative colitis, Greenwood, IN Stacey Nagel, mother of a person with type 1 diabetes, Belle Harbor, NY Stahis Panagides, Ph.D., Parkinson’s disease, Bethesda, MD Stephanie Shavers, type 1 diabetes, Olathe, KS Steven Alton, severe migraines, Albuquerque, NM Steven Craig Hadfield, rare blood cancer and type 2 diabetes, Charlotte, NC Sue Knipmeyer, diabetes, Fargo, ND Sue Lee, plaque psoriasis, Crestwood, KY Susan Fariss, metastatic breast cancer, Washington, DC Taylor Dean, erythromelalgia and allodynia, Jackson, MI Therese Humphrey Ball, multiple sclerosis, Ogden Dunes, IN Toni Neill, multiple sclerosis, Petoskey, MI Tony Mills, diabetes, reactive respiratory disease, kidney disease, high blood pressure, and heart and thyroid complications, Rockport, TX Tori Saylor, multiple sclerosis, Washington, DC Travis Paulson, type 1 diabetes, Eveleth, MN Valerie Gacula, rheumatoid arthritis, fibromyalgia, and bipolar disorder, Long Beach, CA Vanessa Ladson, fibromyalgia and lupus, Dover, DE Victoria Stuessel, multiple sclerosis, La Puente, CA Vivian Fiorito, chronic obstructive pulmonary disease, Benton, AR Xanadu Roque, type 1 diabetes, Gainesville, FL CC: The Honorable Joseph R. Biden, President of the United States The Honorable Richard Neal, Chair, House Ways and Means Committee The Honorable Frank Pallone, Chair, House Energy and Commerce Committee The Honorable Charles Schumer, Majority Leader, United States Senate The Honorable Ron Wyden, Chair, Senate Finance Committee |
| ### |
WASHINGTON, D.C. — Patients For Affordable Drugs Now released a new video that exposes how Big Pharma’s recent multi-million dollar ad campaigns are full of lies about how Medicare negotiation would limit access to drugs. The 40-second video, featuring cancer patient and P4ADNow founder David Mitchell, explains that congressional Democrats’ plan to allow Medicare to negotiate lower drug prices would increase access as drugs become more affordable.
The video comes on the heels of Patients For Affordable Drugs’ new fact checkthat breaks down six false claims in pharma-funded ads, including misleading claims about the implications of repealing the non-interference clause and direct Medicare negotiation.
Both the new video and the fact check debunk industry ads currently being run by PhRMA itself, Medicare Today, the Pharmaceutical Industry Labor-Management Association, the American Conservative Union, and other industry-allied groups that total more than $18 million this year.
Read the video transcript below and watch the full video here.
Transcript:
I have incurable cancer, and prescription drugs are keeping me alive.
No one cares more about access to drugs than patients like me.
Big Pharma’s running ads saying the Democrats in Congress want to limit access to prescription drugs.
It’s not true.
High prices limit access to medications people need right now.
The Democratic plan would actually improve access by allowing Medicare to negotiate lower prices.
Nothing in the plan limits access to drugs.
It’s another Big Pharma big lie. Don’t fall for it.
###